Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 2/20 | 0.59 |
| ▸ | RAB9A | P51151 | 2/20 | 0.59 |
| ▸ | PKM | P14618 | 2/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.58 |
| ▸ | CTNNB1 | P35222 | 10/20 | 0.57 |
| ▸ | WNT3A | P56704 | 8/20 | 0.57 |
| ▸ | ATM | Q13315 | 1/20 | 0.56 |
| ▸ | HPGD | P15428 | 1/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | THRB | P10828 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4032725 | 0.92 | KDM4E (0.56) | NPC1RAB9APKMSMN1; SMN2KDM4E | |
| SCHEMBL6794849 | 0.88 | CTNNB1 (0.48) | NPC1RAB9APKMSMN1; SMN2KDM4E | |
| SCHEMBL21917869 | 0.83 | RAB9A (0.54) | NPC1RAB9APKMSMN1; SMN2KDM4E | |
| SCHEMBL5695788 | 0.79 | CTNNB1 (0.67) | NPC1RAB9APKMSMN1; SMN2KDM4E | |
| SCHEMBL22394792 | 0.77 | CTNNB1 (0.58) | NPC1RAB9APKMSMN1; SMN2KDM4E | |
| SCHEMBL3425193 | 0.74 | NPC1 (1.00) | NPC1RAB9APKMSMN1; SMN2KDM4E | |
| SCHEMBL22394673 | 0.74 | SMN1; SMN2 (0.61) | NPC1RAB9APKMSMN1; SMN2KDM4E | |
| SCHEMBL29858593 | 0.74 | NPC1 (1.00) | NPC1RAB9APKMSMN1; SMN2KDM4E | |
| SCHEMBL14592085 | 0.74 | MEN1 (0.48) | NPC1RAB9ASMN1; SMN2KDM4EHPGD | |
| SCHEMBL5199273 | 0.74 | GRM5 (0.55) | NPC1RAB9AATMGAATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040152738-A1 | Pyridyl-substituted triazoles as tgf inhibitors | SMITHKLINE BEECHAM CORPORATION | 2004-08-05 | — | — | US | disclosed |
| EP-1335916-A1 | PYRIDYL-SUBSTITUTED TRIAZOLES AS TGF INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2003-08-20 | — | — | EP | disclosed |
| WO-2002040476-A1 | PYRIDYL-SUBSTITUTED TRIAZOLES AS TGF INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2002-05-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040152738-A1 | Pyridyl-substituted triazoles as tgf inhibitors | TGFBR1, TGFBR2, SMAD3 | NPC1 251/4885RAB9A 3867/4885PKM 4027/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.